Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

One of the most buzz-worthy skincare ingredients at the moment is all about plumping and replenishing the skin: peptides.

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating resp ...

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...

Treatment shows potential to slow the progression of human degenerative eye diseases, including retinitis pigmentosa.

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Treatment shows potential to slow the progression of human degenerative eye diseases, including retinitis pigmentosa.

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Type 2 diabetes mellitus (T2DM) is a prevalent yet complex metabolic disorder that has shown a rising incidence over the past few decades. Recent research has identified flavonoids as compounds ...

Scientists have developed a cutting-edge way to fight stubborn UTIs by using nanogels to deliver antibiotics directly to ...